149 related articles for article (PubMed ID: 24074238)
1. Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer.
Koster R; van Vugt MA; Timmer-Bosscha H; Gietema JA; de Jong S
Expert Rev Mol Med; 2013 Sep; 15():e12. PubMed ID: 24074238
[TBL] [Abstract][Full Text] [Related]
2. Testicular germ cell tumours: the paradigm of chemo-sensitive solid tumours.
di Pietro A; Vries EG; Gietema JA; Spierings DC; de Jong S
Int J Biochem Cell Biol; 2005 Dec; 37(12):2437-56. PubMed ID: 16099193
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin resistance in germ cell tumours: models and mechanisms.
Jacobsen C; Honecker F
Andrology; 2015 Jan; 3(1):111-21. PubMed ID: 25546083
[TBL] [Abstract][Full Text] [Related]
4. [Molecular bases of platinum-resistance in testicular cancer].
Germà-Lluch JR; Piulats JM
Arch Esp Urol; 2013 Jun; 66(5):524-35. PubMed ID: 23793770
[TBL] [Abstract][Full Text] [Related]
5. Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer.
Koster R; di Pietro A; Timmer-Bosscha H; Gibcus JH; van den Berg A; Suurmeijer AJ; Bischoff R; Gietema JA; de Jong S
J Clin Invest; 2010 Oct; 120(10):3594-605. PubMed ID: 20811155
[TBL] [Abstract][Full Text] [Related]
6. Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer.
Mueller T; Voigt W; Simon H; Fruehauf A; Bulankin A; Grothey A; Schmoll HJ
Cancer Res; 2003 Jan; 63(2):513-21. PubMed ID: 12543810
[TBL] [Abstract][Full Text] [Related]
7. Seladin-1 and testicular germ cell tumours: new insights into cisplatin responsiveness.
Nuti F; Luciani P; Marinari E; Erdei E; Bak M; Deledda C; Rosati F; Mazzinghi B; Danza G; Stoop H; Looijenga LH; Peri A; Serio M; Krausz C
J Pathol; 2009 Dec; 219(4):491-500. PubMed ID: 19844922
[TBL] [Abstract][Full Text] [Related]
8. p53-Dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells.
Zamble DB; Jacks T; Lippard SJ
Proc Natl Acad Sci U S A; 1998 May; 95(11):6163-8. PubMed ID: 9600935
[TBL] [Abstract][Full Text] [Related]
9. Expression of proteins correlated with the unique cisplatin-sensitivity of testicular cancer.
de Graaf TW; de Jong S; de Vries EG; Mulder NH
Anticancer Res; 1997; 17(1A):369-75. PubMed ID: 9066679
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin hypersensitivity of testicular germ cell tumors is determined by high constitutive Noxa levels mediated by Oct-4.
Gutekunst M; Mueller T; Weilbacher A; Dengler MA; Bedke J; Kruck S; Oren M; Aulitzky WE; van der Kuip H
Cancer Res; 2013 Mar; 73(5):1460-9. PubMed ID: 23302226
[TBL] [Abstract][Full Text] [Related]
11. Pro- and anti-apoptotic effects of p53 in cisplatin-treated human testicular cancer are cell context-dependent.
di Pietro A; Koster R; Boersma-van Eck W; Dam WA; Mulder NH; Gietema JA; de Vries EG; de Jong S
Cell Cycle; 2012 Dec; 11(24):4552-62. PubMed ID: 23165211
[TBL] [Abstract][Full Text] [Related]
12. Curing metastatic cancer: lessons from testicular germ-cell tumours.
Masters JR; Köberle B
Nat Rev Cancer; 2003 Jul; 3(7):517-25. PubMed ID: 12835671
[TBL] [Abstract][Full Text] [Related]
13. Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation.
Houldsworth J; Xiao H; Murty VV; Chen W; Ray B; Reuter VE; Bosl GJ; Chaganti RS
Oncogene; 1998 May; 16(18):2345-9. PubMed ID: 9620551
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin based chemotherapy in testicular cancer patients: long term platinum excretion and clinical effects.
Hohnloser JH; Schierl R; Hasford B; Emmerich B
Eur J Med Res; 1996 Sep; 1(11):509-14. PubMed ID: 9438151
[TBL] [Abstract][Full Text] [Related]
15. Testicular cancer: Determinants of cisplatin sensitivity and novel therapeutic opportunities.
de Vries G; Rosas-Plaza X; van Vugt MATM; Gietema JA; de Jong S
Cancer Treat Rev; 2020 Aug; 88():102054. PubMed ID: 32593915
[TBL] [Abstract][Full Text] [Related]
16. Role of MEK/ERK pathway in the MAD2-mediated cisplatin sensitivity in testicular germ cell tumour cells.
Fung MK; Cheung HW; Ling MT; Cheung AL; Wong YC; Wang X
Br J Cancer; 2006 Aug; 95(4):475-84. PubMed ID: 16880791
[TBL] [Abstract][Full Text] [Related]
17. Loss of drug-induced activation of the CD95 apoptotic pathway in a cisplatin-resistant testicular germ cell tumor cell line.
Spierings DC; de Vries EG; Vellenga E; de Jong S
Cell Death Differ; 2003 Jul; 10(7):808-22. PubMed ID: 12815464
[TBL] [Abstract][Full Text] [Related]
18. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
[TBL] [Abstract][Full Text] [Related]
19. Strong apoptotic response of testis tumor cells following cisplatin treatment.
Köberle B; Usanova S; Piee-Staffa A; Heinicke U; Clauss P; Brozovic A; Kaina B
Int Urol Nephrol; 2024 Mar; 56(3):1007-1017. PubMed ID: 37891379
[TBL] [Abstract][Full Text] [Related]
20. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line.
Kelland LR; Mistry P; Abel G; Freidlos F; Loh SY; Roberts JJ; Harrap KR
Cancer Res; 1992 Apr; 52(7):1710-6. PubMed ID: 1312897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
